Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

ENPP1 inhibitor with ultralong drug-target residence time as an innate immune checkpoint blockade cancer therapy.

Cell reports. Medicine·2025
Same author

ENPP1 inhibitor with ultralong drug-target residence time as an innate immune checkpoint blockade cancer therapy.

bioRxiv : the preprint server for biology·2025
Same author

TGF-β trap of AdAPT-001 turns up the heat on tumors and turns down checkpoint blocker resistance.

Journal for immunotherapy of cancer·2024
Same author

CAR expression in invasive breast carcinoma and its effect on adenovirus transduction efficiency.

Breast cancer research : BCR·2024
Same author

Lost at SCLC: a review of potential platinum sensitizers.

Cancer metastasis reviews·2024
Same author

Hypothesis: AdAPT-001 and pseudoprogression - when seeing is not necessarily believing.

Journal for immunotherapy of cancer·2024

Related Experiment Video

Updated: Apr 21, 2026

An Integrated Platform for Genome-wide Mapping of Chromatin States Using High-throughput ChIP-sequencing in Tumor Tissues
10:41

An Integrated Platform for Genome-wide Mapping of Chromatin States Using High-throughput ChIP-sequencing in Tumor Tissues

Published on: April 5, 2018

11.0K

Rewriting the epigenetic code for tumor resensitization: a review.

Bryan Oronsky1, Neil Oronsky2, Jan Scicinski1

  • 1RadioRx Inc, Mountain View, CA, USA.

Translational Oncology
|November 13, 2014
PubMed
Summary

Epigenetic therapies like HDAC inhibitors and DNMT inhibitors may reverse cancer chemoresistance. This offers hope for treating metastatic cancer by resensitizing tumors to previously failed treatments.

More Related Videos

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

8.1K
Genome-Wide CRISPR Screen for Unveiling Radiosensitive and Radioresistant Genes
08:32

Genome-Wide CRISPR Screen for Unveiling Radiosensitive and Radioresistant Genes

Published on: May 23, 2025

1.5K

Related Experiment Videos

Last Updated: Apr 21, 2026

An Integrated Platform for Genome-wide Mapping of Chromatin States Using High-throughput ChIP-sequencing in Tumor Tissues
10:41

An Integrated Platform for Genome-wide Mapping of Chromatin States Using High-throughput ChIP-sequencing in Tumor Tissues

Published on: April 5, 2018

11.0K
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

8.1K
Genome-Wide CRISPR Screen for Unveiling Radiosensitive and Radioresistant Genes
08:32

Genome-Wide CRISPR Screen for Unveiling Radiosensitive and Radioresistant Genes

Published on: May 23, 2025

1.5K

Area of Science:

  • Oncology
  • Epigenetics
  • Cancer Therapeutics

Background:

  • Acquired chemoresistance is considered irreversible in metastatic cancer.
  • This dogma limits treatment options and therapeutic rechallenge.
  • Epigenetic therapies offer a novel approach to modify gene expression patterns.

Purpose of the Study:

  • To explore mechanisms of epigenetic agents in reversing chemoresistance.
  • To highlight recent findings on reprogramming the tumor microenvironment.
  • To discuss revising the treatment paradigm for metastatic cancers.

Main Methods:

  • Review of epigenetic therapies including HDAC inhibitors (entinostat, vorinostat) and DNMT inhibitors (decitabine, 5-azacytidine).
  • Exploration of redox modulators (RRx-001) for tumor microenvironment reprogramming.
  • Analysis of potential to resensitize tumors to previously failed chemotherapies.

Main Results:

  • Epigenetic therapies may reprogram the tumor microenvironment from refractory to nonrefractory.
  • Small molecule agents show potential in overcoming acquired chemoresistance.
  • Evidence suggests a possibility to restore tumor sensitivity to anticancer drugs.

Conclusions:

  • Epigenetic reprogramming offers a promising strategy to manage metastatic cancer.
  • Revisiting the "once burned forever spurned" paradigm is warranted.
  • Active resensitization attempts with failed chemotherapies should be considered.